Precigen, Inc. (NASDAQ:PGEN) is one of the best multibagger penny stocks to buy according to analysts. On August 15, the ...

Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

EDT Precigen (PGEN) files to sell 143.81M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, ...

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...

In a report released today, Jason Butler from Citizens JMP maintained a Buy rating on Precigen, with a price target of $8.00. The company’s shares closed today at $2.95. Take advantage of TipRanks ...

Precigen (PGEN) stock jumps as the FDA approves the company's gene therapy Papzimeos for adults with recurrent respiratory ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Precigen, Inc. (NASDAQ:PGEN) stands ...

A downtrend has been apparent in Precigen, Inc. (PGEN) lately. While the stock has lost 19.9% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Get the latest updated list of insiders for Precigen, Inc. (PGEN). Find out the total of insider shares held, purchased and sold.